Business Context and Reporting Period
This Form 8-K Current Report was filed by Cara Therapeutics, Inc. on August 4, 2017, covering events occurring on July 31, 2017. The filing primarily addresses executive leadership changes within the company's financial and strategic management.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- Appointment of New CFO: Mani Mohindru, Ph.D., was appointed as Chief Financial Officer and Chief Strategy Officer, effective August 15, 2017.
- Departure of Former CFO: Josef Schoell retired and resigned as Chief Financial Officer, effective August 15, 2017.
- Compensation Structure: Dr. Mohindru's agreement includes a $420,000 annual base salary, a $25,000 signing bonus, a target annual discretionary bonus of 40% of base salary, and an option to purchase 385,000 shares of common stock vesting over four years.
Outlook, Risks, and Contingencies
Severance and Change in Control: The employment agreement outlines specific severance obligations. If terminated without cause after August 15, 2018, Dr. Mohindru is entitled to nine months of base salary, 50% of the target bonus, and COBRA premiums. In the event of a change in control followed by termination without cause, 100% of unvested options would vest immediately. If terminated without cause prior to August 15, 2018, the severance is reduced to three months of base salary.
Transition: Mr. Schoell is expected to enter a consulting agreement to assist with the transition of duties. The company confirmed there are no disputes regarding financial reporting or compliance matters.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for the 385,000 stock options granted to Dr. Mohindru.
- Confirm the terms of the consulting agreement to be entered into with retiring CFO Josef Schoell.
- Review the full text of the employment agreement (Exhibit 10.1) for detailed definitions of "termination without cause" and performance goals.
- Monitor future filings for the impact of this leadership change on the company's financial strategy and capital raising efforts.